AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - AC Imm

AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.

Raccontata dabenzinga.com